| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA502092
Max Phase: Preclinical
Molecular Formula: C32H39ClN6O3
Molecular Weight: 591.16
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: Cc1cc(N2CCC(N3C[C@@H](C)O[C@@H](C)C3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12
Standard InChI: InChI=1S/C32H39ClN6O3/c1-19-13-25(38-11-8-24(9-12-38)39-17-20(2)42-21(3)18-39)15-27-30(19)37-31(36-27)29-26(7-10-34-32(29)41)35-16-28(40)22-5-4-6-23(33)14-22/h4-7,10,13-15,20-21,24,28,40H,8-9,11-12,16-18H2,1-3H3,(H,36,37)(H2,34,35,41)/t20-,21+,28-/m1/s1
Standard InChI Key: VVICOEQHILEAPE-PHVLTXCSSA-N
Associated Targets(Human)
Insulin-like growth factor I receptor 8605 Activities
Cytochrome P450 3A4 53859 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Insulin-like growth factor 1 receptor 35 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mus musculus 284745 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 591.16 | Molecular Weight (Monoisotopic): 590.2772 | AlogP: 5.10 | #Rotatable Bonds: 7 |
| Polar Surface Area: 109.51 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 4 |
| #RO5 Violations: 2 | HBA (Lipinski): 9 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 9.58 | CX Basic pKa: 8.26 | CX LogP: 3.56 | CX LogD: 2.79 |
| Aromatic Rings: 4 | Heavy Atoms: 42 | QED Weighted: 0.24 | Np Likeness Score: -1.01 |
References
| 1. Zimmermann K, Wittman MD, Saulnier MG, Velaparthi U, Langley DR, Sang X, Frennesson D, Carboni J, Li A, Greer A, Gottardis M, Attar RM, Yang Z, Balimane P, Discenza LN, Vyas D.. (2008) Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors., 18 (14): [PMID:18572407] [10.1016/j.bmcl.2008.05.104] |
Source
Source(1):